Moreover, we found that the NF-κB signaling was activated in response to in vitro decitabine treatment in CD4+ T cells from responsive patients, which was related to an increased frequency of peripheral IFN-γ+CD4+ T cells following in vivo decitabine therapy in ovarian cancer patients, further confirming the IκBα/NF-κB/IFN-γ regulation mechanism by low-dose decitabine in CD4+ T cells. The gene discussed is NFKBIA; the disease is ovarian carcinoma.